Pastila Wegovy pentru slăbit: pacienții au pierdut în medie 13,6% din greutate. Cât costă noul tratament

A new phase in obesity treatment begins in Europe with Wegovy's oral form available in Germany since September 1. The medication, requiring a prescription, is priced between 170 and 280 euros. Semaglutide, the active ingredient, mimics an intestinal hormone that promotes satiety, helping reduce hunger and food intake. Unlike the injectable version, the oral tablets are for adults only and must be taken daily. Clinical trials showed that adults using oral semaglutide lost an average of 13.6% of their body weight. Side effects include nausea and gastrointestinal issues. Experts emphasize that obesity medications should complement a healthy diet and exercise, not serve as quick weight-loss solutions. The global market for weight-loss drugs is projected to reach $100 billion by 2030, with increasing competition in the sector.